Cytotoxicity of and DNA adduct formation by ellipticine and its micellar form in human leukemia cells in vitro

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11310%2F15%3A10313412" target="_blank" >RIV/00216208:11310/15:10313412 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/15:10313412 RIV/62156489:43210/15:43908489 RIV/00064203:_____/15:10313412 RIV/00216305:26620/15:PU126794

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Cytotoxicity of and DNA adduct formation by ellipticine and its micellar form in human leukemia cells in vitro

Popis výsledku v původním jazyce

OBJECTIVES: The improvements of cancer treatment are the major challenge in oncology research. Nanocarriers are one of the promising approaches to selectively target tumor cells, frequently leading to improve drug therapeutic index. Ellipticine is an anticancer agent that functions through multiple mechanisms. Here, the toxic effects of an anticancer drug ellipticine encapsulated in a micellar nanotransporter and free ellipticine on human HL-60 leukemia cells and formation of ellipticine-derived DNA adducts by both forms of the drug in these cells were investigated. METHODS: The toxicity of modified ellipticine on cells was compared to that of free ellipticine using the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl tetrazoliumbromide cytotoxicity assay. 32P-postlabeling was utilized to determine ellipticine-DNA adducts in treated cells. RESULTS: The comparison of efficiencies of free ellipticine and ellipticine-micelles [the poly(ethylene oxide)- block-poly(allyl glycidyl ether) block cop

Název v anglickém jazyce

Cytotoxicity of and DNA adduct formation by ellipticine and its micellar form in human leukemia cells in vitro

Popis výsledku anglicky

OBJECTIVES: The improvements of cancer treatment are the major challenge in oncology research. Nanocarriers are one of the promising approaches to selectively target tumor cells, frequently leading to improve drug therapeutic index. Ellipticine is an anticancer agent that functions through multiple mechanisms. Here, the toxic effects of an anticancer drug ellipticine encapsulated in a micellar nanotransporter and free ellipticine on human HL-60 leukemia cells and formation of ellipticine-derived DNA adducts by both forms of the drug in these cells were investigated. METHODS: The toxicity of modified ellipticine on cells was compared to that of free ellipticine using the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl tetrazoliumbromide cytotoxicity assay. 32P-postlabeling was utilized to determine ellipticine-DNA adducts in treated cells. RESULTS: The comparison of efficiencies of free ellipticine and ellipticine-micelles [the poly(ethylene oxide)- block-poly(allyl glycidyl ether) block cop

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neuroendocrinology Letters

ISSN

0172-780X

e-ISSN

—

Svazek periodika

36

Číslo periodika v rámci svazku

Suppl. 1

Stát vydavatele periodika

SE - Švédské království

Počet stran výsledku

7

Strana od-do

22-28

Kód UT WoS článku

000369404400003

EID výsledku v databázi Scopus

2-s2.0-84959341884